Prices delayed by at least 15 minutes | Print
Reneuron Group PLC (RENE)
ORD 1POpen
3.45p
Previous close
3.45p
Trade high
3.5p
Volume
177,620
Year high
11.50p
Year low
3.28p
Dividend yield
-
Market capitalisation
£1.93 mn
P/E ratio
-
ISIN
GB00BF5G6K95
This share can be held in a Dealing accountISALifetime ISAJISASIPPand can be used with Dividend reinvestment
Share price
Company profile
ReNeuron Group PLC is engaged in the field of biotechnology. Its core activities include the research and clinical development of cell-based therapeutics. The company product pipeline includes the human retinal progenitor cell line (hRPC) and CTX neural cell line. It derives revenue from UK and U.S. The company is mainly focusing on the treatment of stroke disability, inherited retinal diseases, and cancer.
News
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2024 AJ Bell. All rights reserved.